NEW YORK (GenomeWeb) – Cambridge, UK-based Congenica today announced it has raised £2.2 million ($3.3 million) in Series A financing from Amadeus Capital Partners and Cambridge Innovation Capital.

The firm has developed Sapientia, a platform to screen whole-genome sequencing data to identify novel genetic mutations and highlight those associated with genetic disorders.

Congenica, a spinout of The Wellcome Trust Sanger Institute, will use the funds to further develop its technology, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.